nodes	percent_of_prediction	percent_of_DWPC	metapath
Rivaroxaban—Lipase increased—Telbivudine—hepatitis B	0.0428	0.0607	CcSEcCtD
Rivaroxaban—Amylase increased—Telbivudine—hepatitis B	0.0264	0.0375	CcSEcCtD
Rivaroxaban—F10—blood plasma—hepatitis B	0.0212	0.336	CbGeAlD
Rivaroxaban—F10—Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus—F2—hepatitis B	0.0153	0.0662	CbGpPWpGaD
Rivaroxaban—Amylase increased—Lamivudine—hepatitis B	0.0149	0.0211	CcSEcCtD
Rivaroxaban—CYP2J2—Xenobiotics—CYP2A6—hepatitis B	0.0145	0.0626	CbGpPWpGaD
Rivaroxaban—F10—Removal of aminoterminal propeptides from gamma-carboxylated proteins—F2—hepatitis B	0.0139	0.0602	CbGpPWpGaD
Rivaroxaban—F10—Gamma-carboxylation of protein precursors—F2—hepatitis B	0.0139	0.0602	CbGpPWpGaD
Rivaroxaban—Gingival bleeding—Lamivudine—hepatitis B	0.0125	0.0177	CcSEcCtD
Rivaroxaban—Hepatic function abnormal—Adefovir Dipivoxil—hepatitis B	0.0124	0.0176	CcSEcCtD
Rivaroxaban—F10—Gamma-carboxylation, transport, and amino-terminal cleavage of proteins—F2—hepatitis B	0.0119	0.0513	CbGpPWpGaD
Rivaroxaban—Blood creatinine increased—Entecavir—hepatitis B	0.0104	0.0148	CcSEcCtD
Rivaroxaban—Blood creatinine increased—Adefovir Dipivoxil—hepatitis B	0.0102	0.0144	CcSEcCtD
Rivaroxaban—Abdominal pain upper—Entecavir—hepatitis B	0.0102	0.0144	CcSEcCtD
Rivaroxaban—Pain in extremity—Telbivudine—hepatitis B	0.00914	0.013	CcSEcCtD
Rivaroxaban—Renal failure—Entecavir—hepatitis B	0.00843	0.0119	CcSEcCtD
Rivaroxaban—Abdominal pain upper—Telbivudine—hepatitis B	0.00835	0.0118	CcSEcCtD
Rivaroxaban—Renal failure—Adefovir Dipivoxil—hepatitis B	0.00822	0.0117	CcSEcCtD
Rivaroxaban—Haematuria—Entecavir—hepatitis B	0.00818	0.0116	CcSEcCtD
Rivaroxaban—Jaundice—Adefovir Dipivoxil—hepatitis B	0.00816	0.0116	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Entecavir—hepatitis B	0.00811	0.0115	CcSEcCtD
Rivaroxaban—F10—Common Pathway—F2—hepatitis B	0.008	0.0346	CbGpPWpGaD
Rivaroxaban—Haematuria—Adefovir Dipivoxil—hepatitis B	0.00798	0.0113	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Adefovir Dipivoxil—hepatitis B	0.00791	0.0112	CcSEcCtD
Rivaroxaban—Rectal haemorrhage—Lamivudine—hepatitis B	0.00786	0.0111	CcSEcCtD
Rivaroxaban—Sinusitis—Adefovir Dipivoxil—hepatitis B	0.00785	0.0111	CcSEcCtD
Rivaroxaban—Oropharyngeal pain—Lamivudine—hepatitis B	0.0078	0.0111	CcSEcCtD
Rivaroxaban—F10—blood—hepatitis B	0.00776	0.123	CbGeAlD
Rivaroxaban—Hepatitis—Entecavir—hepatitis B	0.0077	0.0109	CcSEcCtD
Rivaroxaban—Hepatitis—Adefovir Dipivoxil—hepatitis B	0.00751	0.0106	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Adefovir Dipivoxil—hepatitis B	0.00742	0.0105	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Adefovir Dipivoxil—hepatitis B	0.00738	0.0105	CcSEcCtD
Rivaroxaban—Urethral disorder—Adefovir Dipivoxil—hepatitis B	0.00736	0.0104	CcSEcCtD
Rivaroxaban—CYP3A5—Aflatoxin activation and detoxification—GGT2—hepatitis B	0.00718	0.031	CbGpPWpGaD
Rivaroxaban—F10—Beta2 integrin cell surface interactions—CD40LG—hepatitis B	0.00704	0.0304	CbGpPWpGaD
Rivaroxaban—Immune system disorder—Entecavir—hepatitis B	0.00695	0.00985	CcSEcCtD
Rivaroxaban—Renal failure—Telbivudine—hepatitis B	0.00692	0.00981	CcSEcCtD
Rivaroxaban—F10—Intrinsic Pathway—F2—hepatitis B	0.00682	0.0295	CbGpPWpGaD
Rivaroxaban—F10—Blood Clotting Cascade—F2—hepatitis B	0.00682	0.0295	CbGpPWpGaD
Rivaroxaban—Hepatobiliary disease—Telbivudine—hepatitis B	0.00666	0.00944	CcSEcCtD
Rivaroxaban—Back pain—Adefovir Dipivoxil—hepatitis B	0.00632	0.00896	CcSEcCtD
Rivaroxaban—Hepatitis—Telbivudine—hepatitis B	0.00632	0.00896	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Telbivudine—hepatitis B	0.00621	0.00881	CcSEcCtD
Rivaroxaban—CYP3A5—blood plasma—hepatitis B	0.00611	0.0969	CbGeAlD
Rivaroxaban—F10—liver—hepatitis B	0.00606	0.0963	CbGeAlD
Rivaroxaban—Anaemia—Adefovir Dipivoxil—hepatitis B	0.00604	0.00856	CcSEcCtD
Rivaroxaban—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP2A6—hepatitis B	0.00601	0.026	CbGpPWpGaD
Rivaroxaban—CYP2J2—Oxidation by Cytochrome P450—CYP2A6—hepatitis B	0.00593	0.0256	CbGpPWpGaD
Rivaroxaban—Mediastinal disorder—Telbivudine—hepatitis B	0.0057	0.00808	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Entecavir—hepatitis B	0.00567	0.00803	CcSEcCtD
Rivaroxaban—F10—PTM: gamma carboxylation, hypusine formation and arylsulfatase activation—F2—hepatitis B	0.00562	0.0243	CbGpPWpGaD
Rivaroxaban—Chest pain—Adefovir Dipivoxil—hepatitis B	0.00557	0.00789	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Adefovir Dipivoxil—hepatitis B	0.00553	0.00783	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Entecavir—hepatitis B	0.00547	0.00775	CcSEcCtD
Rivaroxaban—Infection—Entecavir—hepatitis B	0.00543	0.0077	CcSEcCtD
Rivaroxaban—CYP2J2—Arachidonic acid metabolism—GGT1—hepatitis B	0.00543	0.0235	CbGpPWpGaD
Rivaroxaban—Nervous system disorder—Entecavir—hepatitis B	0.00536	0.0076	CcSEcCtD
Rivaroxaban—Back pain—Telbivudine—hepatitis B	0.00533	0.00755	CcSEcCtD
Rivaroxaban—Skin disorder—Entecavir—hepatitis B	0.00531	0.00753	CcSEcCtD
Rivaroxaban—Muscle spasms—Telbivudine—hepatitis B	0.00529	0.0075	CcSEcCtD
Rivaroxaban—Nervous system disorder—Adefovir Dipivoxil—hepatitis B	0.00523	0.00742	CcSEcCtD
Rivaroxaban—Skin disorder—Adefovir Dipivoxil—hepatitis B	0.00518	0.00735	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Telbivudine—hepatitis B	0.00511	0.00724	CcSEcCtD
Rivaroxaban—CYP2J2—liver—hepatitis B	0.00497	0.0789	CbGeAlD
Rivaroxaban—Malaise—Telbivudine—hepatitis B	0.00496	0.00704	CcSEcCtD
Rivaroxaban—CYP2J2—Phase 1 - Functionalization of compounds—CYP2A6—hepatitis B	0.00487	0.0211	CbGpPWpGaD
Rivaroxaban—Dyspepsia—Entecavir—hepatitis B	0.00481	0.00682	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Entecavir—hepatitis B	0.00472	0.00669	CcSEcCtD
Rivaroxaban—Fatigue—Entecavir—hepatitis B	0.00472	0.00668	CcSEcCtD
Rivaroxaban—Abdominal pain upper—Lamivudine—hepatitis B	0.00471	0.00667	CcSEcCtD
Rivaroxaban—Dyspepsia—Adefovir Dipivoxil—hepatitis B	0.0047	0.00666	CcSEcCtD
Rivaroxaban—Chest pain—Telbivudine—hepatitis B	0.00469	0.00664	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Telbivudine—hepatitis B	0.00465	0.0066	CcSEcCtD
Rivaroxaban—Discomfort—Telbivudine—hepatitis B	0.00463	0.00656	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Adefovir Dipivoxil—hepatitis B	0.00461	0.00653	CcSEcCtD
Rivaroxaban—F10—Formation of Fibrin Clot (Clotting Cascade)—F2—hepatitis B	0.0046	0.0199	CbGpPWpGaD
Rivaroxaban—CYP3A4—blood plasma—hepatitis B	0.00458	0.0727	CbGeAlD
Rivaroxaban—Gastrointestinal pain—Entecavir—hepatitis B	0.00447	0.00634	CcSEcCtD
Rivaroxaban—Nervous system disorder—Telbivudine—hepatitis B	0.00441	0.00624	CcSEcCtD
Rivaroxaban—CYP2J2—Metapathway biotransformation—AKR1B1—hepatitis B	0.0044	0.019	CbGpPWpGaD
Rivaroxaban—Skin disorder—Telbivudine—hepatitis B	0.00436	0.00618	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Adefovir Dipivoxil—hepatitis B	0.00436	0.00618	CcSEcCtD
Rivaroxaban—Abdominal pain—Entecavir—hepatitis B	0.00432	0.00613	CcSEcCtD
Rivaroxaban—CYP2J2—Biological oxidations—GGT2—hepatitis B	0.00427	0.0185	CbGpPWpGaD
Rivaroxaban—Abdominal pain—Adefovir Dipivoxil—hepatitis B	0.00422	0.00598	CcSEcCtD
Rivaroxaban—CYP3A5—Xenobiotics—CYP2A6—hepatitis B	0.00417	0.018	CbGpPWpGaD
Rivaroxaban—CYP3A5—Tamoxifen metabolism—CYP2A6—hepatitis B	0.00401	0.0173	CbGpPWpGaD
Rivaroxaban—Dyspepsia—Telbivudine—hepatitis B	0.00395	0.0056	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Lamivudine—hepatitis B	0.00394	0.00558	CcSEcCtD
Rivaroxaban—Asthenia—Entecavir—hepatitis B	0.00392	0.00556	CcSEcCtD
Rivaroxaban—Renal failure—Lamivudine—hepatitis B	0.0039	0.00553	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Telbivudine—hepatitis B	0.00388	0.0055	CcSEcCtD
Rivaroxaban—Fatigue—Telbivudine—hepatitis B	0.00387	0.00549	CcSEcCtD
Rivaroxaban—Jaundice—Lamivudine—hepatitis B	0.00387	0.00548	CcSEcCtD
Rivaroxaban—Pain—Telbivudine—hepatitis B	0.00384	0.00545	CcSEcCtD
Rivaroxaban—Asthenia—Adefovir Dipivoxil—hepatitis B	0.00383	0.00543	CcSEcCtD
Rivaroxaban—Pruritus—Adefovir Dipivoxil—hepatitis B	0.00378	0.00535	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Lamivudine—hepatitis B	0.00375	0.00532	CcSEcCtD
Rivaroxaban—Epistaxis—Lamivudine—hepatitis B	0.00374	0.00531	CcSEcCtD
Rivaroxaban—Diarrhoea—Entecavir—hepatitis B	0.00374	0.0053	CcSEcCtD
Rivaroxaban—Sinusitis—Lamivudine—hepatitis B	0.00372	0.00528	CcSEcCtD
Rivaroxaban—Agranulocytosis—Lamivudine—hepatitis B	0.0037	0.00525	CcSEcCtD
Rivaroxaban—Feeling abnormal—Telbivudine—hepatitis B	0.0037	0.00525	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Telbivudine—hepatitis B	0.00367	0.00521	CcSEcCtD
Rivaroxaban—Diarrhoea—Adefovir Dipivoxil—hepatitis B	0.00365	0.00517	CcSEcCtD
Rivaroxaban—Dizziness—Entecavir—hepatitis B	0.00362	0.00513	CcSEcCtD
Rivaroxaban—Hepatitis—Lamivudine—hepatitis B	0.00356	0.00505	CcSEcCtD
Rivaroxaban—Abdominal pain—Telbivudine—hepatitis B	0.00355	0.00503	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Lamivudine—hepatitis B	0.0035	0.00496	CcSEcCtD
Rivaroxaban—Vomiting—Entecavir—hepatitis B	0.00348	0.00493	CcSEcCtD
Rivaroxaban—Rash—Entecavir—hepatitis B	0.00345	0.00489	CcSEcCtD
Rivaroxaban—Dermatitis—Entecavir—hepatitis B	0.00345	0.00488	CcSEcCtD
Rivaroxaban—Headache—Entecavir—hepatitis B	0.00343	0.00486	CcSEcCtD
Rivaroxaban—CYP3A5—Aflatoxin activation and detoxification—GGT1—hepatitis B	0.00339	0.0147	CbGpPWpGaD
Rivaroxaban—Vomiting—Adefovir Dipivoxil—hepatitis B	0.00339	0.00481	CcSEcCtD
Rivaroxaban—Erythema multiforme—Lamivudine—hepatitis B	0.00337	0.00478	CcSEcCtD
Rivaroxaban—Rash—Adefovir Dipivoxil—hepatitis B	0.00336	0.00477	CcSEcCtD
Rivaroxaban—Dermatitis—Adefovir Dipivoxil—hepatitis B	0.00336	0.00476	CcSEcCtD
Rivaroxaban—Headache—Adefovir Dipivoxil—hepatitis B	0.00334	0.00474	CcSEcCtD
Rivaroxaban—CYP3A4—Aflatoxin activation and detoxification—GGT2—hepatitis B	0.00334	0.0144	CbGpPWpGaD
Rivaroxaban—Nausea—Entecavir—hepatitis B	0.00325	0.0046	CcSEcCtD
Rivaroxaban—ABCB1—blood plasma—hepatitis B	0.00324	0.0515	CbGeAlD
Rivaroxaban—Asthenia—Telbivudine—hepatitis B	0.00322	0.00457	CcSEcCtD
Rivaroxaban—Immune system disorder—Lamivudine—hepatitis B	0.00322	0.00456	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Lamivudine—hepatitis B	0.00321	0.00455	CcSEcCtD
Rivaroxaban—Pruritus—Telbivudine—hepatitis B	0.00318	0.0045	CcSEcCtD
Rivaroxaban—Nausea—Adefovir Dipivoxil—hepatitis B	0.00317	0.00449	CcSEcCtD
Rivaroxaban—CYP3A4—Farnesoid X Receptor  Pathway—NR0B2—hepatitis B	0.0031	0.0134	CbGpPWpGaD
Rivaroxaban—F10—Complement and Coagulation Cascades—F2—hepatitis B	0.0031	0.0134	CbGpPWpGaD
Rivaroxaban—Diarrhoea—Telbivudine—hepatitis B	0.00307	0.00436	CcSEcCtD
Rivaroxaban—Back pain—Lamivudine—hepatitis B	0.003	0.00425	CcSEcCtD
Rivaroxaban—Muscle spasms—Lamivudine—hepatitis B	0.00298	0.00423	CcSEcCtD
Rivaroxaban—Dizziness—Telbivudine—hepatitis B	0.00297	0.00421	CcSEcCtD
Rivaroxaban—F10—Hemostasis—HBE1—hepatitis B	0.00296	0.0128	CbGpPWpGaD
Rivaroxaban—Ill-defined disorder—Lamivudine—hepatitis B	0.00288	0.00408	CcSEcCtD
Rivaroxaban—Anaemia—Lamivudine—hepatitis B	0.00287	0.00406	CcSEcCtD
Rivaroxaban—CYP3A5—Constitutive Androstane Receptor Pathway—CYP2A6—hepatitis B	0.00287	0.0124	CbGpPWpGaD
Rivaroxaban—Vomiting—Telbivudine—hepatitis B	0.00286	0.00405	CcSEcCtD
Rivaroxaban—Angioedema—Lamivudine—hepatitis B	0.00283	0.00402	CcSEcCtD
Rivaroxaban—Rash—Telbivudine—hepatitis B	0.00283	0.00401	CcSEcCtD
Rivaroxaban—Dermatitis—Telbivudine—hepatitis B	0.00283	0.00401	CcSEcCtD
Rivaroxaban—Headache—Telbivudine—hepatitis B	0.00281	0.00399	CcSEcCtD
Rivaroxaban—Malaise—Lamivudine—hepatitis B	0.0028	0.00397	CcSEcCtD
Rivaroxaban—Syncope—Lamivudine—hepatitis B	0.00278	0.00394	CcSEcCtD
Rivaroxaban—Loss of consciousness—Lamivudine—hepatitis B	0.00273	0.00386	CcSEcCtD
Rivaroxaban—Nausea—Telbivudine—hepatitis B	0.00267	0.00378	CcSEcCtD
Rivaroxaban—Chest pain—Lamivudine—hepatitis B	0.00264	0.00374	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—hepatitis B	0.00262	0.00372	CcSEcCtD
Rivaroxaban—Discomfort—Lamivudine—hepatitis B	0.00261	0.0037	CcSEcCtD
Rivaroxaban—CYP2J2—Biological oxidations—CYP2A6—hepatitis B	0.00259	0.0112	CbGpPWpGaD
Rivaroxaban—Dry mouth—Lamivudine—hepatitis B	0.00258	0.00366	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Lamivudine—hepatitis B	0.00253	0.00359	CcSEcCtD
Rivaroxaban—Oedema—Lamivudine—hepatitis B	0.00253	0.00359	CcSEcCtD
Rivaroxaban—Infection—Lamivudine—hepatitis B	0.00252	0.00356	CcSEcCtD
Rivaroxaban—Shock—Lamivudine—hepatitis B	0.00249	0.00353	CcSEcCtD
Rivaroxaban—Nervous system disorder—Lamivudine—hepatitis B	0.00248	0.00352	CcSEcCtD
Rivaroxaban—Skin disorder—Lamivudine—hepatitis B	0.00246	0.00349	CcSEcCtD
Rivaroxaban—Hypotension—Lamivudine—hepatitis B	0.00237	0.00335	CcSEcCtD
Rivaroxaban—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—hepatitis B	0.00232	0.01	CbGpPWpGaD
Rivaroxaban—Dyspnoea—Lamivudine—hepatitis B	0.00226	0.0032	CcSEcCtD
Rivaroxaban—CYP3A5—blood—hepatitis B	0.00224	0.0355	CbGeAlD
Rivaroxaban—Dyspepsia—Lamivudine—hepatitis B	0.00223	0.00316	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Lamivudine—hepatitis B	0.00219	0.0031	CcSEcCtD
Rivaroxaban—Fatigue—Lamivudine—hepatitis B	0.00218	0.00309	CcSEcCtD
Rivaroxaban—Pain—Lamivudine—hepatitis B	0.00217	0.00307	CcSEcCtD
Rivaroxaban—Constipation—Lamivudine—hepatitis B	0.00217	0.00307	CcSEcCtD
Rivaroxaban—ABCB1—Constitutive Androstane Receptor Pathway—CYP2A6—hepatitis B	0.00216	0.00935	CbGpPWpGaD
Rivaroxaban—Feeling abnormal—Lamivudine—hepatitis B	0.00209	0.00296	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Lamivudine—hepatitis B	0.00207	0.00293	CcSEcCtD
Rivaroxaban—CYP2J2—Biological oxidations—GGT1—hepatitis B	0.00202	0.00874	CbGpPWpGaD
Rivaroxaban—Urticaria—Lamivudine—hepatitis B	0.00201	0.00285	CcSEcCtD
Rivaroxaban—Abdominal pain—Lamivudine—hepatitis B	0.002	0.00284	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—HLA-DPA1—hepatitis B	0.002	0.00863	CbGpPWpGaD
Rivaroxaban—CYP3A4—Xenobiotics—CYP2A6—hepatitis B	0.00194	0.00839	CbGpPWpGaD
Rivaroxaban—CYP3A4—Tamoxifen metabolism—CYP2A6—hepatitis B	0.00187	0.00807	CbGpPWpGaD
Rivaroxaban—Hypersensitivity—Lamivudine—hepatitis B	0.00187	0.00264	CcSEcCtD
Rivaroxaban—Asthenia—Lamivudine—hepatitis B	0.00182	0.00257	CcSEcCtD
Rivaroxaban—Pruritus—Lamivudine—hepatitis B	0.00179	0.00254	CcSEcCtD
Rivaroxaban—CYP3A5—liver—hepatitis B	0.00175	0.0278	CbGeAlD
Rivaroxaban—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2A6—hepatitis B	0.00173	0.00749	CbGpPWpGaD
Rivaroxaban—Diarrhoea—Lamivudine—hepatitis B	0.00173	0.00246	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—AKR1B1—hepatitis B	0.00171	0.0074	CbGpPWpGaD
Rivaroxaban—CYP3A5—Oxidation by Cytochrome P450—CYP2A6—hepatitis B	0.00171	0.00739	CbGpPWpGaD
Rivaroxaban—CYP3A4—blood—hepatitis B	0.00168	0.0266	CbGeAlD
Rivaroxaban—Dizziness—Lamivudine—hepatitis B	0.00167	0.00237	CcSEcCtD
Rivaroxaban—Vomiting—Lamivudine—hepatitis B	0.00161	0.00228	CcSEcCtD
Rivaroxaban—Rash—Lamivudine—hepatitis B	0.0016	0.00226	CcSEcCtD
Rivaroxaban—Dermatitis—Lamivudine—hepatitis B	0.0016	0.00226	CcSEcCtD
Rivaroxaban—Headache—Lamivudine—hepatitis B	0.00159	0.00225	CcSEcCtD
Rivaroxaban—CYP3A4—Aflatoxin activation and detoxification—GGT1—hepatitis B	0.00158	0.00682	CbGpPWpGaD
Rivaroxaban—Nausea—Lamivudine—hepatitis B	0.0015	0.00213	CcSEcCtD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—CYP2A6—hepatitis B	0.00141	0.00607	CbGpPWpGaD
Rivaroxaban—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—hepatitis B	0.00133	0.00576	CbGpPWpGaD
Rivaroxaban—CYP3A4—liver—hepatitis B	0.00131	0.0208	CbGeAlD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—HNF4A—hepatitis B	0.00129	0.00557	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—AKR1B1—hepatitis B	0.00127	0.00548	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—GGT2—hepatitis B	0.00123	0.00532	CbGpPWpGaD
Rivaroxaban—ABCB1—blood—hepatitis B	0.00119	0.0189	CbGeAlD
Rivaroxaban—F10—Hemostasis—HSPA5—hepatitis B	0.00103	0.00444	CbGpPWpGaD
Rivaroxaban—ABCB1—liver—hepatitis B	0.000929	0.0148	CbGeAlD
Rivaroxaban—F10—Hemostasis—IFNB1—hepatitis B	0.000926	0.004	CbGpPWpGaD
Rivaroxaban—F10—Post-translational protein modification—F2—hepatitis B	0.00092	0.00397	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—HLA-DPB1—hepatitis B	0.000917	0.00396	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—IFNA1—hepatitis B	0.000903	0.0039	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—IFNA2—hepatitis B	0.000841	0.00363	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—HSPA5—hepatitis B	0.000808	0.00349	CbGpPWpGaD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—hepatitis B	0.000806	0.00348	CbGpPWpGaD
Rivaroxaban—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—hepatitis B	0.000795	0.00344	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—GGT1—hepatitis B	0.000776	0.00335	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—AKR1B1—hepatitis B	0.000762	0.00329	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—CYP2A6—hepatitis B	0.000746	0.00323	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GGT2—hepatitis B	0.000731	0.00316	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—CD40LG—hepatitis B	0.000676	0.00292	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—IL10—hepatitis B	0.000676	0.00292	CbGpPWpGaD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—hepatitis B	0.000653	0.00282	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—FASLG—hepatitis B	0.000629	0.00272	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—FAS—hepatitis B	0.000606	0.00262	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—NOS2—hepatitis B	0.000599	0.00259	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—HLA-A—hepatitis B	0.000596	0.00258	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—AKR1B1—hepatitis B	0.000589	0.00255	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—GGT1—hepatitis B	0.000583	0.00252	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—GGT2—hepatitis B	0.000573	0.00248	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—F2—hepatitis B	0.000555	0.0024	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—HNF4A—hepatitis B	0.000551	0.00238	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—NOS2—hepatitis B	0.000548	0.00237	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—HLA-DRB1—hepatitis B	0.000545	0.00235	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—ALB—hepatitis B	0.000461	0.00199	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CYP2A6—hepatitis B	0.000443	0.00191	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—F2—hepatitis B	0.000436	0.00189	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—ALB—hepatitis B	0.000413	0.00178	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GOT2—hepatitis B	0.0004	0.00173	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—IFNG—hepatitis B	0.000398	0.00172	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—IL2—hepatitis B	0.000374	0.00161	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—IL2—hepatitis B	0.000353	0.00153	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—CYP2A6—hepatitis B	0.000347	0.0015	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GGT1—hepatitis B	0.000346	0.00149	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GOT1—hepatitis B	0.000346	0.00149	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	0.000315	0.00136	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—hepatitis B	0.00031	0.00134	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—hepatitis B	0.000299	0.00129	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—TGFB1—hepatitis B	0.000291	0.00126	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—CTNNB1—hepatitis B	0.000284	0.00123	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—TGFB1—hepatitis B	0.000276	0.00119	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—GGT1—hepatitis B	0.000271	0.00117	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—TNF—hepatitis B	0.000257	0.00111	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—TP53—hepatitis B	0.00024	0.00104	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—AKR1B1—hepatitis B	0.00022	0.00095	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GGT2—hepatitis B	0.000211	0.00091	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—ALB—hepatitis B	0.000184	0.000795	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—hepatitis B	0.000168	0.000728	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—AKR1B1—hepatitis B	0.000166	0.000717	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—hepatitis B	0.000164	0.000711	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—hepatitis B	0.000164	0.000709	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—hepatitis B	0.000163	0.000706	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GGT2—hepatitis B	0.000159	0.000687	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PTEN—hepatitis B	0.00014	0.000606	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—hepatitis B	0.000136	0.000588	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP2A6—hepatitis B	0.000128	0.000552	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—hepatitis B	0.000127	0.000549	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GOT2—hepatitis B	0.000115	0.000499	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—hepatitis B	0.000112	0.000484	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—AKR1B1—hepatitis B	0.000102	0.000441	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GGT1—hepatitis B	9.96e-05	0.000431	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GOT1—hepatitis B	9.96e-05	0.000431	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GGT2—hepatitis B	9.79e-05	0.000423	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP2A6—hepatitis B	9.63e-05	0.000416	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GOT2—hepatitis B	8.71e-05	0.000376	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—ALB—hepatitis B	8.54e-05	0.000369	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GOT1—hepatitis B	7.52e-05	0.000325	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GGT1—hepatitis B	7.52e-05	0.000325	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP2A6—hepatitis B	5.93e-05	0.000256	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GOT2—hepatitis B	5.37e-05	0.000232	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ALB—hepatitis B	5.3e-05	0.000229	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GGT1—hepatitis B	4.63e-05	0.0002	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GOT1—hepatitis B	4.63e-05	0.0002	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PTEN—hepatitis B	4.04e-05	0.000175	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ALB—hepatitis B	4e-05	0.000173	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PTEN—hepatitis B	3.05e-05	0.000132	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ALB—hepatitis B	2.46e-05	0.000106	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PTEN—hepatitis B	1.88e-05	8.12e-05	CbGpPWpGaD
